[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478465":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":29,"responsibleParty":48,"collaborators":25,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":25,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":25,"enrollmentInfo":61,"targetDuration":25,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":25,"overallStatus":32,"whyStopped":25,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Air Force Military Medical University, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CS","ACTIVE_COMPARATOR","low-dose corticosteroids monotherapy",[13],"Drug: Prednisolone",{"label":15,"type":10,"description":16,"interventionNames":17},"CS+CTX","low-dose corticosteroids combined with cyclophosphamide",[18],"Drug: Prednisolone plus Cyclophosphamide",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Prednisolone","RAS blockade as much as tolerated or allowed",[9],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Prednisolone plus Cyclophosphamide",[15],[30],{"facility":31,"status":32,"city":33,"state":25,"zip":25,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"AFMMU","RECRUITING","Xi'an","China","CN",{"type":37,"coordinates":38},"Point",[39,40],108.92861,34.25833,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":46,"phoneExt":25,"email":47},"Shiren Sun","CONTACT","84775197","jiaqing0808@163.com",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Shiren sun","Chief","100478465","phase-3-efficacy-of-immunosuppressive-therapy-for-iga-nephropathy-with-stage-3-or-4-ckd-100478465",false,"NCT05510323","Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD","Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney Disease","Inclusion Criteria:\n\n* Biopsy-proven IgA nephropathy;\n* Proteinuria ≥1.0g\u002Fday while receiving maximum tolerated dose of RAS blockade;\n* Estimated glomerular filtration rate 15-60 ml\u002Fmin\u002F1.73\u002Fm2.\n\nExclusion Criteria:\n\n* Indication or contraindication for immunosuppressive therapy with corticosteroids\n* Use of corticosteroids and other immunosuppressive drugs within the last 1 year\n* Current unstable kidney function for other reasons\n* Under 18 years old\n* Patients with secondary IgAN\n* Patients who are unlikely to comply with the study protocol in the view of the treating physician","ALL","18 Years",{"count":62,"type":63},208,"ESTIMATED","INTERVENTIONAL",[66],"PHASE3","The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.",[69],"Glomerulonephritis, IGA","2024-05-03",{"date":72,"type":73},"2024-05-06","ACTUAL",{"date":75,"type":73},"2024-02-01",{"date":77,"type":63},"2028-08",{"name":5,"class":6},1]